# US 2021/0330758 A1 · Treatment for bk polyomavirus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330758 A1
- Document ID: US20210330758A1
- Status: Published application
- Kind: A1
- Application number: 17/135,962
- Filed: 2020-12-28
- Published: 2021-10-28
- Earliest claimed: 2013-06-10
- Assignees: Ansun Biopharma, Inc.
- Applicants: Ansun Biopharma, Inc.
- Inventors: Ronald B. Moss
- Web page: https://patentgrep.com/patent/US20210330758A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- C07K 14/485: Epidermal growth factor [EGF], i.e. urogastrone
- C12N 9/2405: {Glucanases}
- C12Y 302/01018: Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides novel compositions and methods for treating infection by a viral pathogen, e.g., a BK or JC polyomavirus, using agents having sialidase activity. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen.

## Claims

### Claim 1

A method of treating an infection or reducing the risk or severity of infection by a JC polyomavirus or a JC polyomavirus-associated disorder in a subject, the method comprising administering to the subject an effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 13 or SEQ ID NO:14.

### Claim 2 (depends on 1)

The method of claim 1, comprising administering a composition comprising microparticles comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 13 or SEQ ID NO:14.

### Claim 3 (depends on 2)

The method of claim 2, wherein the agent is not systemically administered.

### Claim 4 (depends on 2)

The method of claim 2, wherein the subject is immunocompromised.

### Claim 5 (depends on 1)

The method of claim 1, wherein the infection is associated with an event selected from the group consisting of: an HIV infection, cessation of immunosuppressive therapy, commencement of antiviral therapy, and monoclonal antibody autoimmune disease therapy.

### Claim 6 (depends on 4)

The method of claim 4, wherein the subject is a transplant patient undergoing immunosuppressive therapy.

### Claim 7 (depends on 4)

The method of claim 4, wherein the subject is being treated with an immunomodulatory agent that reduces one or more aspects of immune function.

### Claim 8 (depends on 7)

The method of claim 7, wherein the immunomodulatory agent is selected from the group consisting of natalizumab, rituximab, efalizumab and infliximab.

### Claim 9 (depends on 1)

The method of claim 1, wherein the JC polyomavirus is actively replicating in the subject.

### Claim 10 (depends on 1)

The method of claim 1, wherein the disorder is progressive multifocal leukoencephalopathy.

### Claim 11 (depends on 1)

The method of claim 1, wherein the disorder is granule cell neuronopathy.

### Claim 12 (depends on 1)

The method of claim 1, wherein the disorder is encephalopathy.

### Claim 13 (depends on 1)

The method of claim 1, wherein the disorder is meningitis.

### Claim 14 (depends on 1)

The method of claim 1, wherein the disorder is immune reconstitution inflammatory syndrome.